A new report in Obstetrics & Gynecology highlights the potential of extended-release buprenorphine as a safer, simpler option for managing opioid use disorder (OUD) during pregnancy and postpartum . In 15 women treated with the monthly injectable formulation , challenges like nausea, multiple daily dosing, and persistent cravings linked to sublingual therapy were successfully overcome. All participants achieved full adherence, stopped nonprescribed opioid use, and showed reduced overall substance use—with no maternal or neonatal side effects reported.
The findings suggest that a once-monthly injection could transform perinatal addiction care by improving treatment consistency, safety, and recovery outcomes for both mother and baby. To read more; Click here Could simplifying OUD treatment to a single monthly dose be the key to safer pregnancies and stronger recoveries? ##Reference##…
